Skip to Main Content

Opinions+

Perspectives on issues affecting biopharma and health care.

Latest

First Opinion Cheri Banks

STAT Plus: Five things FDA ad comm members want

First Opinion Jack Hooper

STAT Plus: What does the presidential election mean for ICHRA and the health insurance market?

First Opinion Kendalle Burlin O’Connell

STAT Plus: How to keep the BIOSECURE Act from hobbling U.S. biotech and pharma

First Opinion Sarah Emond

STAT Plus: What the newly released Medicare prices for 10 drugs do and don’t tell us

Opinions+ Priya Baraniak

STAT Plus: Cell donors are essential for new therapies. They need to be taken care of

Opinions+ Bruce Leuchter

STAT Plus: Private equity and neuroscience: a novel approach to developing new treatments for neurological disorders

Opinions+ Ashu Singhal and Sajith Wickramasekara

STAT Plus: Could billions of dollars in AI funding lead to the same number of new drugs?

Opinions+ Hope Meely

STAT Plus: Unmasking the ‘centricity’ illusion in clinical trials

All Coverage

Opinions+ Wendy Cheng

STAT Plus: How AI can help satisfy FDA’s drug, device diversity requirements

Opinions+ Kyle H. Sheetz and Robert M. Wachter

STAT Plus: Medical devices makers are trying to take a page from Uber’s playbook

advertisement

First Opinion Amit Etkin

STAT Plus: It’s time to rethink everything about our approach to psychiatric drug development

Opinions+ John Whyte

STAT Plus: Some countries are moving to digital prescription drug information for patients. The U.S. shouldn’t follow suit

First Opinion Christopher Palatucci

STAT Plus: The necessary roughness of 2023 has set up a very promising 2024 for biotech jobs

First Opinion Shirley Leung

STAT Plus: Dana-Farber CEO Laurie Glimcher has always been a trailblazer and a risk taker

First Opinion Peter Shen

STAT Plus: Health care AI requires a new Hippocratic oath

First Opinion Jeremy L. Shane

STAT Plus: A bold approach to pay for weight loss drugs for everyone who needs them

Opinions+ Paul Jones

STAT Plus: The PATCH Act’s approach to securing medical devices actually gives malicious actors a blueprint

First Opinion Tommy Bramley, Herbert Altmann, and Casper Paardekooper

STAT Plus: How to make the EU’s new Joint Clinical Assessment process work for industry — and for patients

First Opinion Brian Finrow

STAT Plus: Preventive drugs may be the best solution to the antibiotic resistance crisis

First Opinion Vijay Ramakrishnan

STAT Plus: How payer-participating trials could help transform clinical research on FDA-approved drugs

First Opinion Leah Christl

STAT Plus: The problem with potential changes to the biosimilar regulatory framework

First Opinion Rachel King and Peter L. Saltonstall

STAT Plus: The IRA needs changes to better support patients with rare diseases

First Opinion Paul Hudson

STAT Plus: Sanofi CEO Paul Hudson: The right way to bring AI into pharma

First Opinion Anna Sparrow

STAT Plus: One way to create resilient drug supply chains: incentivize predictive models

First Opinion Owen Tripp

STAT Plus: How I’m helping companies think through whether they should cover GLP-1s like Ozempic for employees

First Opinion Gloria Coronado and Leslie Bienen

STAT Plus: An overlooked way to make participants in clinical trials look more like America

Opinions+ Ben Green

STAT Plus: At-home clinical trials are the future

Opinions+ Peter G. Lurie and Beth Ellikidis

STAT Plus: Where are the guidelines for the production of animals with intentional genomic alterations?

Opinions+ Dave Greenwald

STAT Plus: 3 keys to successful biopharma-academia drug development collaborations